Lara Sullivan, M.D. 13D and 13G filings for Pyxis Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-02 9:25 pm Purchase |
2025-03-31 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 7,543,007 11.210% |
918,308 (+13.86%) |
Filing |
| 2024-12-23 6:31 pm Purchase |
2024-12-23 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 6,624,699 10.300% |
1,135,000 (+20.68%) |
Filing |
| 2024-04-03 5:10 pm Purchase |
2024-03-26 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 5,489,699 8.890% |
1,319,425 (+31.64%) |
Filing |
| 2023-04-04 4:58 pm Purchase |
2023-03-24 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 4,170,274 10.200% |
703,379 (+20.29%) |
Filing |
| 2022-05-23 06:15 am Purchase |
2022-03-31 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 3,466,895 9.600% |
1,153,531 (+49.86%) |
Filing |
| 2021-10-21 6:52 pm Purchase |
2021-10-13 | 13D | Pyxis Oncology, Inc. PYXS |
Lara Sullivan, M.D. | 2,313,364 6.660% |
2,313,364 (New Position) |
Filing |